TY  - JOUR
AU  - Ferrer, Irene
AU  - Quintanal-Villalonga, Álvaro
AU  - Molina-Pinelo, Sonia
AU  - Garcia-Heredia, Jose Manuel
AU  - Perez, Marco
AU  - Suárez, Rocío
AU  - Ponce-Aix, Santiago
AU  - Paz-Ares, Luis
AU  - Carnero, Amancio
PY  - 2018
DO  - 10.1186/s13046-018-0871-7
UR  - http://hdl.handle.net/10668/12848
T2  - Journal of experimental & clinical cancer research : CR
AB  - The high incidence and mortality of lung tumours is a major health problem. Therefore, the identification both of biomarkers predicting efficacy for therapies in use and of novel efficacious therapeutic agents is crucial to increase patient survival....
LA  - en
KW  - Biomarkers
KW  - Lung cancer
KW  - PDZK1IP1
KW  - Treatment efficacy
KW  - Adenocarcinoma
KW  - Adenocarcinoma of Lung
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Biomarkers, Tumor
KW  - Bortezomib
KW  - Cell Line, Tumor
KW  - Cisplatin
KW  - ErbB Receptors
KW  - Female
KW  - Gene Expression Regulation, Neoplastic
KW  - Humans
KW  - Kaplan-Meier Estimate
KW  - Lung Neoplasms
KW  - Male
KW  - Membrane Proteins
KW  - Middle Aged
KW  - Prognosis
KW  - Proteasome Inhibitors
KW  - Protein Kinase Inhibitors
KW  - Xenograft Model Antitumor Assays
TI  - MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma.
TY  - research article
VL  - 37
ER  -